Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Clinical trial NCT07703436 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07703436
Sponsor: Nuvation Bio Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Grade 2 IDH1-mutant Glioma Grade 3 IDH1-mutant Glioma Glioma IDH1-mutant Glioma Oligodendroglioma Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted Astrocytoma IDH Mutant Grade 3 Astrocytoma IDH Mutant Grade 2

Start date: 2027-03-01
Primary completion: 2030-09-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.